Cargando…
Prophylactic Anticoagulation With Intermediate-Dose Certoparin in Vascular-Risk Pregnancies—The PACER-VARP Registry
The management of pregnant women at increased risk of thromboembolic/other vascular events is still a matter of debate. In a single-center, retrospective, observational trial, we analyzed the safety and efficacy of prophylactic anticoagulation with certoparin in pregnant women at intermediate- or hi...
Autores principales: | Grünewald, Martin, Häge, Esther, Lehnert, Stephanie, Maier, Christiane, Schimke, Alexandra, Bramlage, Peter, Güth, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150601/ https://www.ncbi.nlm.nih.gov/pubmed/34027682 http://dx.doi.org/10.1177/10760296211016550 |
Ejemplares similares
-
A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study
por: Dorsch, Oliver, et al.
Publicado: (2012) -
Rab40C is a novel Varp-binding protein that promotes proteasomal degradation of Varp in melanocytes
por: Yatsu, Ayaka, et al.
Publicado: (2015) -
Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement
por: Bramlage, Peter, et al.
Publicado: (2012) -
Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease – a post-hoc analysis of the PARAT trial
por: Melzer, Nima, et al.
Publicado: (2014) -
Patient engagement – the PaCER model
por: Hylton, Chris
Publicado: (2015)